UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 84 WEEKS FROM THE SELECT-MONOTHERAPY STUDY

被引:3
作者
Smolen, J. S. [1 ]
Emery, P. [2 ,3 ]
Rigby, W. [4 ]
Tanaka, Y. [5 ]
Vargas, J. Ignacio [6 ]
Damjanov, N. [7 ]
Jain, M. [8 ]
Song, Y. [9 ]
Khan, N. [9 ]
Enejosa, J. J. [9 ]
Cohen, S. B. [10 ]
机构
[1] Med Univ Vienna, Vienna, Austria
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] NIHR Biomed Res Ctr, Leeds, W Yorkshire, England
[4] Dartmouth Coll, Hanover, NH 03755 USA
[5] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan
[6] Quantum Res, Puerto Varas, Chile
[7] Univ Belgrade, Inst Rheumatol, Sch Med, Belgrade, Serbia
[8] Great Lakes Clin Trials, Chicago, IL USA
[9] AbbVie Inc, N Chicago, IL USA
[10] Metroplex Clin Res Ctr, Dallas, TX USA
关键词
D O I
10.1136/annrheumdis-2020-eular.961
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
THU0213
引用
收藏
页码:327 / 328
页数:2
相关论文
共 50 条
[41]   UPADACITINIB MONOTHERAPY IMPROVES PATIENT-REPORTED OUTCOMES IN METHOTREXATE-NAIVE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM SELECT-EARLY [J].
Strand, Vibeke ;
Tundia, Namita ;
Radominski, Sebastiao ;
Friedman, Alan ;
Dunlap, Kendall ;
Goldschmidt, Deborah ;
Bergman, Martin .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 :372-373
[42]   INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1 YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAM [J].
Peterfy, Charles ;
Genovese, Mark C. ;
Song, In-Ho ;
Friedman, Alan ;
Hall, Stephen ;
Mysler, Eduardo ;
Durez, Patrick ;
Baraliakos, Xenofon ;
Enejosa, Jose Jeffrey ;
Shaw, Tim ;
Li Yihan ;
Su Chen ;
Strand, Vibeke .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 :369-370
[43]   Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial [J].
Jain, Siddharth ;
Dhir, Varun ;
Aggarwal, Amita ;
Gupta, Ranjan ;
Laishangtham, Bidya ;
Khullar, Aastha ;
Naidu, Shankar ;
Dhawan, Veena ;
Sharma, Shefali ;
Sharma, Aman ;
Jain, Sanjay .
ARTHRITIS & RHEUMATOLOGY, 2022, 74 :1818-1819
[44]   Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE) [J].
Hideto Kameda ;
Tsutomu Takeuchi ;
Kunihiro Yamaoka ;
Motohiro Oribe ;
Mitsuhiro Kawano ;
Masayuki Yokoyama ;
Aileen L. Pangan ;
Yuko Konishi ;
Sebastian Meerwein ;
Yoshiya Tanaka .
Arthritis Research & Therapy, 23
[45]   Impact of 24-or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials [J].
Strand, Vibeke ;
Tundia, Namita ;
Friedman, Alan ;
Camp, Heidi ;
Suboticki, Jessica ;
Goldschmidt, Debbie ;
Fernan, Catherine ;
Bergman, Martin .
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[46]   Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE) [J].
Kameda, Hideto ;
Takeuchi, Tsutomu ;
Yamaoka, Kunihiro ;
Oribe, Motohiro ;
Kawano, Mitsuhiro ;
Yokoyama, Masayuki ;
Pangan, Aileen L. ;
Konishi, Yuko ;
Meerwein, Sebastian ;
Tanaka, Yoshiya .
ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
[47]   Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study [J].
Li, Z. ;
Hu, J. ;
Bao, C. ;
Li, X. ;
Li, X. ;
Xu, J. ;
Spindler, A. J. ;
Zhang, X. ;
Xu, J. ;
He, D. ;
Li, Z. ;
Wang, G. ;
Yang, Y. ;
Wu, H. ;
Ji, F. ;
Tao, H. ;
Zhan, L. ;
Bai, F. ;
Rooney, T. P. ;
Zerbini, C. A. F. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (04) :732-741
[48]   SAFETY AND EFFECTIVENESS OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-COMPARE STUDY [J].
Fleischmann, Roy ;
Enejosa, Jeffrey ;
Song, In-Ho ;
Mysler, Eduardo ;
Bessette, Louis ;
Peterfy, Charles ;
Durez, Patrick ;
Ostor, Andrew ;
Li Yihan ;
Zhou, Yijie ;
Genovese, Mark C. .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 :744-745
[49]   Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study [J].
Jones, G. ;
Sebba, A. ;
Gu, J. ;
Lowenstein, M. B. ;
Calvo, A. ;
Gomez-Reino, J. J. ;
Siri, D. A. ;
Tomsic, M. ;
Alecock, E. ;
Woodworth, T. ;
Genovese, M. C. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) :88-96
[50]   Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial [J].
Hambardzumyan, Karen ;
Bolce, Rebecca J. ;
Wallman, Johan K. ;
van Vollenhoven, Ronald F. ;
Saevarsdottir, Saedis .
JOURNAL OF RHEUMATOLOGY, 2019, 46 (06) :555-563